Critical Analysis: TetraLogic Pharmaceuticals (OTCMKTS:TLOG) versus Mainz Biomed (NASDAQ:MYNZ)

Mainz Biomed (NASDAQ:MYNZ) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Valuation & Earnings

This table compares Mainz Biomed and TetraLogic Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$895,479.00	4.34	-$26.30 million	($1.64)	-0.20
TetraLogic Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

TetraLogic Pharmaceuticals has lower revenue, but higher earnings than Mainz Biomed.

Profitability

This table compares Mainz Biomed and TetraLogic Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	-2,934.82%	-488.05%	-145.77%
TetraLogic Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Mainz Biomed and TetraLogic Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	0	1	1	0	2.50
TetraLogic Pharmaceuticals	0	0	0	0	N/A

Mainz Biomed presently has a consensus target price of $3.00, suggesting a potential upside of 826.50%.

Insider and Institutional Ownership

0.0% of TetraLogic Pharmaceuticals shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 15.4% of TetraLogic Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Mainz Biomed has a beta of 0.09, suggesting that its stock price is 91% less volatile than the S&P 500. Comparatively, TetraLogic Pharmaceuticals has a beta of 2.86, suggesting that its stock price is 186% more volatile than the S&P 500.

Summary

TetraLogic Pharmaceuticals beats Mainz Biomed on 5 of the 8 factors compared between the two stocks.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells. SHAPE is its proprietary histone deacetylase inhibitor for topical use for the treatment of early-stage cutaneous T-cell lymphoma. TetraLogic Pharmaceuticals Corporation has research collaboration with Walter and Eliza Hall Institute of Medical Research to examine SMAC-mimetics, including birinapant in the treatment of infectious disease. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.